Neupro

Parkinson’s Disease

Neupro is used to treat the signs and symptoms of Parkinson’s disease, including both early-stage and advanced-stage conditions. It helps manage motor symptoms such as:

• Shaking or tremors
• Stiffness or muscle rigidity
• Slowed movement
• Balance and coordination issues

Restless Legs Syndrome (RLS)

This medication is also indicated for the treatment of moderate-to-severe primary Restless Legs Syndrome. It helps reduce the strong urge to move the legs and the uncomfortable sensations—such as crawling, tingling, or aching—that typically occur during periods of inactivity or at night.

Administration

Neupro is a transdermal patch that delivers medication through the skin. It is designed to provide a steady release of medicine into the body throughout the day and night.

Mechanism of Action

Neupro belongs to a group of medicines called dopamine agonists. It works by acting in place of dopamine, a naturally occurring chemical messenger in the brain. Dopamine is essential for sending signals that control muscle movement, balance, and walking.

How it Helps Parkinson's Disease

In people with Parkinson's disease, certain nerve cells in the brain that produce dopamine begin to die or malfunction. This leads to a shortage of dopamine, resulting in symptoms like tremors, stiffness, and slow movement. Neupro stimulates the same receptors in the brain that dopamine normally activates, which helps to restore some control over physical movements.

How it Helps Restless Legs Syndrome

The exact cause of Restless Legs Syndrome (RLS) is not fully known, but it is thought to involve imbalances in dopamine levels or how the brain processes dopamine. By mimicking dopamine, Neupro helps reduce the intense urge to move the legs and the uncomfortable sensations that typically occur at night or during periods of rest.

Continuous Delivery

Neupro is a transdermal system, meaning the medication is contained within a patch. Once applied to the skin, the medicine is absorbed continuously into the bloodstream over a 24-hour period. This steady delivery helps maintain more consistent levels of the medication in the body compared to some oral medications that may cause levels to rise and fall quickly.

Common Side Effects

Many people using Neupro experience mild side effects as their body adjusts to the medication. These commonly include:

• Skin reactions where the patch was applied, such as redness, itching, or swelling
• Nausea and vomiting
• Drowsiness or dizziness
• Headache
• Loss of appetite
• Increased sweating
• Swelling of the hands, ankles, or feet
• Difficulty falling or staying asleep

Serious Side Effects

Some side effects can be serious and may require medical attention. Contact a healthcare provider immediately if you experience:

• Falling asleep suddenly during daily activities, such as eating, talking, or driving
• Hallucinations (seeing or hearing things that are not real)
• Confusion, agitation, or aggressive behavior
• New or increased intense urges, such as gambling, binge eating, or sexual urges
• Fainting or feeling very lightheaded, especially when standing up
• Vision changes
• Fast, pounding, or irregular heartbeat
• Chest pain
• Severe skin reactions that do not improve after the patch is removed

Sudden Sleep Onset

Some people using Neupro have reported falling asleep without warning during daily activities, including while driving. This can occur at any time during treatment, even if the person does not feel drowsy beforehand. If a person experiences significant daytime sleepiness or falls asleep during activities that require active participation, discontinuation of the medication may be considered.

Hallucinations and Psychotic Behavior

Neupro may cause hallucinations (seeing or hearing things that are not real) or other psychotic-like behaviors. These symptoms are more common in older adults and those with Parkinson's disease. Confusion, agitation, and aggressive behavior have also been reported. People with a major psychotic disorder generally should not use Neupro due to the risk of exacerbating their condition.

Impulse Control Disorders

Treatment with dopamine agonists like Neupro can lead to intense urges to gamble, increased sexual urges, binge eating, or compulsive spending. Because these urges may not be recognized as abnormal by the person experiencing them, monitoring by family or caregivers is often recommended. Dose reduction or stopping the medication may reverse these behaviors.

MRI and Medical Procedures

The backing of the Neupro patch contains aluminum. To prevent skin burns, the patch must be removed before undergoing an MRI (Magnetic Resonance Imaging) or cardioversion (a procedure to restore heart rhythm). A new patch can be applied after the procedure is complete.

Blood Pressure and Fainting

Neupro can cause orthostatic hypotension, which is a sudden drop in blood pressure when standing up. This may lead to dizziness, lightheadedness, or fainting, especially when first starting the medication or increasing the dose. Syncope (fainting) has been observed in clinical trials for both Parkinson's disease and Restless Legs Syndrome.

Skin Reactions

Application site reactions are common and may include redness, itching, or swelling. Rotating the application site daily is necessary to reduce the risk of severe skin irritation. If a skin rash or irritation persists or spreads, medical evaluation is necessary.

Sulfite Sensitivity

This medication contains sodium metabisulfite, a sulfite that may cause allergic-type reactions, including anaphylaxis or life-threatening asthma attacks, in people who are sensitive to sulfites. Sulfite sensitivity is more common in people with asthma than in those without it.

Restless Legs Syndrome Augmentation

When used for Restless Legs Syndrome (RLS), symptoms may worsen, start earlier in the evening or afternoon, or spread to other parts of the body. This phenomenon is known as augmentation. If this occurs, the treatment plan may need to be re-evaluated.

Pregnancy

There are no adequate and well-controlled studies of Neupro use in pregnant women. In animal studies, rotigotine was associated with decreased fetal weight and delayed bone development at doses higher than those used in humans. Because the risk to a human fetus is unknown, you should inform your healthcare provider if you are pregnant or planning to become pregnant while using this medication.

Breastfeeding

It is not known whether rotigotine passes into human breast milk. Many drugs are excreted in milk, and there is a potential for serious adverse reactions in nursing infants. Additionally, Neupro is a dopamine agonist, a class of medication known to lower prolactin levels, which may interfere with the body's ability to produce breast milk. If you are breastfeeding or plan to breastfeed, discuss the risks and benefits with your doctor to determine the best course of action.

Available Forms

Neupro is available exclusively as a transdermal system. This medication is formulated as a thin, adhesive patch that is applied directly to the skin.

Patch Characteristics

• Transdermal Delivery: The patch is designed to release the active ingredient steadily into the bloodstream through the skin.
• Varying Sizes: The patches are available in different physical sizes. The amount of medication delivered is determined by the surface area of the patch.

The patch is intended for once-daily use and must be replaced every 24 hours to maintain a consistent level of medication in the body.

FDA Approval and Indications

Neupro (rotigotine transdermal system) is approved by the U.S. Food and Drug Administration (FDA) for the treatment of:

• Signs and symptoms of early-stage and advanced-stage Parkinson's disease.
• Moderate-to-severe primary Restless Legs Syndrome (RLS).

Regulatory History

The medication was initially approved in 2007. However, in 2008, the manufacturer voluntarily withdrew the patches from the U.S. market because of a manufacturing issue where the active ingredient formed crystals on the patch, potentially reducing the drug's effectiveness. After a reformulation of the patch and the implementation of specific storage requirements, the FDA re-approved Neupro for use in 2012.

Safety and Monitoring

There are currently no FDA boxed warnings or Risk Evaluation and Mitigation Strategies (REMS) required for Neupro. Regulatory oversight focuses on monitoring for class-wide side effects associated with dopamine agonists, such as sudden sleep onset, hallucinations, and impulse control disorders.

Generic Availability

Neupro is currently available only as a brand-name drug. There is no generic version of the rotigotine transdermal patch available in the United States. Brand-name medications typically have a higher out-of-pocket cost than generic alternatives.

Insurance and Coverage

The cost of Neupro is often determined by your health insurance plan's formulary. Because it is a brand-name drug without a generic competitor, it may be placed on a higher cost-sharing tier, resulting in a higher copayment or coinsurance. Some insurance providers may also require prior authorization before they will agree to cover the medication.

Factors Affecting Price

Several factors can influence the final price you pay for Neupro:

• Dosage Strength: Neupro patches are available in multiple strengths, including 1 mg, 2 mg, 3 mg, 4 mg, 6 mg, and 8 mg. The price may vary depending on the strength your doctor prescribes.
• Pharmacy Choice: Prices for the same medication can differ between retail pharmacies, mail-order pharmacies, and specialty pharmacies.
• Assistance Programs: The manufacturer may offer savings cards or patient assistance programs for eligible individuals to help lower the cost of the prescription.